Cancer Grand Challenges

What Cancer Grand Challenges does

Cancer Grand Challenges is a global research funding initiative co-founded in 2020 by Cancer Research UK and the US National Cancer Institute, with operational roots dating to 2016. Its core function is to identify the toughest unsolved problems in cancer research and award grants of up to $25 million per interdisciplinary team over approximately five years. The initiative is governed by a Scientific Committee chaired by Professor Charles Swanton (with Professor Judy E. Garber as vice-chair) that recommends challenges and reviews proposals; final funding decisions rest with the two co-founders. As of March 2026, the initiative has committed $624 million in cumulative support since 2016, funding 21 teams across 18 challenges, and spanning 34 institutions in 9 countries in its latest round alone.

The "platform" is not a software product but a structured funding and community-orchestration mechanism: a biennial-to-triennial open call invites global researchers to self-assemble interdisciplinary teams, which are reviewed by the Scientific Committee and interviewed before awards. Active challenge areas include cancer avoidance, the dark proteome, mechanisms driving mutational signatures, the nervous system and cancer, rewiring cancer cells, cancer inequities, early-onset cancers, solid tumors in children, T-cell receptors, cachexia, extrachromosomal DNA, and normal phenotypes. The initiative operates an embedded patient advocacy program, a Future Leaders Programme supporting 400+ early-career researchers across 10+ countries, and a conference series (including Cancer and the Host, Spatial Biology, and Future Leaders' Conference). It is supported by a coalition of 15+ named financial partners and donors including The Mark Foundation, KiKa, KWF Dutch Cancer Society, Spanish Association Against Cancer, French National Cancer Institute, and Cancer Research Institute, alongside individual donors such as the Kamini & Vindi Banga Family Trust, Emerson Collective, and the Bowelbabe Fund.

Cancer Grand Challenges is not a revenue-generating entity. Its economics are grant-in, grant-out: philanthropic and governmental inflows from Cancer Research UK, NCI, and partner donors are redistributed as research grants, conference programming, and community infrastructure. Pricing is not applicable — funding amounts are fixed at up to $25M per team over ~5 years. Headcount in firmographic terms (1,001-5,000) appears to conflate the broader investigator community (1,800+ across 107 institutions in 19 countries) with operational staff; the disclosed London-based leadership and program team is materially smaller. The organization is structurally a joint initiative rather than an independent legal entity, with Cancer Research UK responsible for operational delivery including website and day-to-day operations.

Name

Cancer Grand Challenges

Legal name

Cancer Grand Challenges

Website

https://cancergrandchallenges.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Cancer Grand Challenges is a global research funding initiative co-founded by Cancer Research UK and the US National Cancer Institute, awarding up to $25 million per interdisciplinary team to tackle cancer's toughest challenges across 19 countries and 107 institutions.

Ownership category

akta.pro rank

Product category

Cancer Research Funding Initiative

NAICS

Grantmaking Foundations (813211), Voluntary Health Organizations (813212)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Cancer research funding
• Interdisciplinary research grants
• Biomedical research awards
• Team science initiatives
• Global health research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Grants and research funding distribution (the dominant cost — up to $25 million per team over ~5 years), Personnel, Operations (program management, website, application review by Scientific Committee), Marketing or Sales, Infrastructure (conferences and events)

Revenue model

1. Research Funding Distribution: Cancer Grand Challenges operates as a global research funding initiative. It does not generate revenue from products or services but rather receives funding from co-founders Cancer Research UK and the National Cancer Institute, along with a coalition of partners and donors, to award grants to interdisciplinary research teams tackling cancer's toughest challenges.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Cancer Grand Challenges is a global research funding initiative that identifies the toughest challenges in cancer research and empowers interdisciplinary teams to tackle them with awards of up to $25 million over approximately five years. It is not a software product but a coordinated funding and community platform co-founded by Cancer Research UK and the National Cancer Institute, spanning 19 countries and 107 research institutions with over 1,800 investigators.

Product overview

Cancer Grand Challenges is a global research initiative that identifies the toughest challenges in cancer research. It is not a unified software product but rather a funding and collaboration platform that connects researchers across disciplines. The initiative encompasses active challenges (such as Cancer avoidance, The dark proteome, Mechanisms driving mutational signatures, The nervous system and cancer, Rewiring cancer cells, Cancer inequities, Early-onset cancers, Solid tumours in children, T-cell receptors, Cachexia, Extrachromosomal DNA, Normal phenotypes, and Microbiota), concluded challenges (3D tumour mapping, Lethal versus non-lethal cancers, Unusual mutation patterns, Cancer causes, Tissue specificity), and unfunded challenges. The platform facilitates research through team funding, conferences (Cancer and the host, Spatial biology), publications, and community building including Future Leaders programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Grand Challenges Research Funding Program
• Future Leaders Programme
• Cancer Grand Challenges Scientific Conferences

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered co-founder.

• Cancer Research UKco-founderStrategic or Co-development Partner · 1 January 2020Co-founder of Cancer Grand Challenges in 2020. Responsible for the operational delivery of the initiative, including management of the website and day-to-day operations. The world's leading cancer charity dedicated to saving and improving lives through research.
• National Cancer Institute (NCI)co-founderStrategic or Co-development Partner · 1 January 2020Co-founder of Cancer Grand Challenges in 2020. The US federal government's principal agency for cancer research and training, and the largest funder of cancer research in the world.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Stand Up To Cancer: US-based collaborative cancer research funding model that awards multi-year, large-scale, interdisciplinary team grants to tackle high-risk cancer questions. Most directly comparable to Cancer Grand Challenges in mission, funding structure, and team-science approach.
• Cancer Research Institute: US non-profit that funds large-scale, multi-institution cancer immunology research teams and is an active co-funder of Cancer Grand Challenges' ILLUMINE team. Closely comparable in its emphasis on team-based, high-value cancer research grants.
• The Mark Foundation for Cancer Research: US non-profit that co-funds multiple Cancer Grand Challenges teams (SPECIFICANCER, NexTGen, MATCHMAKERS) and independently funds large, multi-year team science grants. Operates a similar model of high-value, multi-institution team awards.
• V Foundation for Cancer Research: Major US cancer research grantmaker that funds individual investigators and collaborative teams across a range of high-impact cancer research questions. Closely comparable mission and grant scale to Cancer Grand Challenges.
• Lustgarten Foundation: Largest private funder of pancreatic cancer research, with a collaborative team-science model and large, multi-year grants to multi-institution teams. Comparable as a disease-focused, team-oriented research funder.

Broad incumbents

• Howard Hughes Medical Institute: Large US biomedical research organization that funds long-term, high-value investigator and team science. Comparable in its scale and long-duration funding model, though broader than cancer alone.
• Wellcome Trust: Major UK-based global health research foundation funding large, long-duration, team-based research across biomedical and population health. Comparable in geography, scale, and team-science model, though not cancer-specific.
• Bill & Melinda Gates Foundation: Largest private philanthropic global health funder, supporting large-scale, multi-institution research consortia with long grant cycles. Comparable in operating scale and team-science grantmaking, though oriented toward infectious disease and global health.

Others

• European Research Council: Public EU funder that awards large, multi-year frontier research grants to individual PIs and teams across Europe. Comparable in its scale of single awards and long funding cycles, though not cancer-specific and not a foundation.
• Chan Zuckerberg Initiative: US philanthropic initiative that funds large, multi-institution biomedical research networks (e.g., CZ Biohub) with long-duration commitments. Comparable in its team-science and network-building model, though broader in scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CancerGrand
• YouTubevimeo.com/cancergrandchallenges
• LinkedInlinkedin.com/company/cancergrandchallenges

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Grand Challenges